Neoplasms – Talk Bio

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

14 hours ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%

J&J brushes off tariff headwinds with raised forecast, oncology surge

1 week ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

FDA clears Exelixis’ TKI for neuroendocrine tumours

1 month ago talkbio0Tagged Approved, Cabometyx, cabozantinib, Exelixis, Neoplasms, Neurosecretory Systems, Protein Tyrosine Kinase, United States Food and Drug Administration

CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor

AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout

1 month ago talkbio0Tagged Acquisition, AstraZeneca, Autoimmune Diseases, Cell Engineering, Cell Therapy, ENaBL Platform, EsoBiotec, in vivo, Neoplasms

AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases

ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera

2 months ago talkbio0Tagged ITM-11, Lutathera, Neoplasms, Neurosecretory Systems, Novartis, Phase 3 COMPETE trial, Radiopharmaceuticals

ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care